Extended-spectrum beta-lactamases: The end of cephalosporins?

Israel Medical Association Journal

Volumn 7, Issue 5, 2005, Pages 336-338

  Colodner, Raul ^a   Raz, Raul ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antibiotics; Bacterial resistance; Carbapenems; Cephalosporins; Extended spectrum lactamases

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; EDITORIAL; ENTEROBACTER; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; ISRAEL; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; POINT MUTATION; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SALMONELLA;

ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMASES; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; HUMANS; ISRAEL; RISK FACTORS;

EID: 18744399027     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Bush K. Is it important to identify extended spectrum beta-lactamase producing isolates? Eur J Clin Microb Infect Dis 1996;15:361-4.
2. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
3. Quinn JP. Clinical strategies for serious infection: a North American perspective. Diagn Microbiol Infect Dis 1998;31:389-95
4. Gianneli D, Tzelepi E, Tzouvelekis LS, Mentis AF. Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals. Eur J Clin Microbiol Infect Dis 1994;13:764-7.
5. Bell JM, Turnidge JD, Jones RN, for the SENTRY Asia-Pacific Participants. Prevalence of extended-spectrum beta-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001. Antimicrob Agents Chemother 2003;47:3989-93.
6. Jacoby G, Bush K. Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor-resistant beta-lactamases. http://www.lahey.org/studies/webt.htm.
7. Tassios PT, Gazouli M, Tzelepi E, et al. Spread of a Salmonella typhimurium clone resistant to expanded-spectrum cephalosporins in three European countries. J Clin Microbiol 1999;37:3774-7.
8. Vahaboglu H, Ozturk R, Aygun Y, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997;41:2265-9.
9. Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ. CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 2000;14:137-42.
10. Bishara J, Livne G, Ashkenazi S, et al. Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. IMAJ 2005; 7:298-301
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;48:933-51.
12. Stobberingh EE, Arends J, Hoogkamp-Korstanie JAA, et al. Occurrence of extended-spectrum beta-lactamases in Dutch hospitals. Infection 1999;27:348-54.
13. Branger C, Lesimple AL, Bruneu B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases in a university hospital. J Med Microbiol 1998;47:201-9.
14. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, for the Sentry APAC Study Group. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002;42:193-8.
15. Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y. Occurrence and phenotypic characteristics of extended-spectrum β-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol 2003;41:155-8
16. Borer A, Gilad J, Menashe G, Peled N, Riesenberg K, Schlaeffer F. Extended-spectrum beta-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit 2002;8:44-7.
17. Colodner R, Keness Y, Chazan B, Raz R. Antimicrobial susceptibility of community-acquired uropathogens in Northern Israel. Int J Antimicrob Agents 2001;18:189-92.
18. Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis 2005;24(1):l7-22.
19. Colodner R, Keller N, Chazan B, Raz R. Sensitivity and cost-effectiveness of different phenotypic methods for the detection and confirmation of extended-spectrum beta-lactamases including an inexpensive novel method. Poster # 1618 Presented at the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, 2004.
20. Schiappa DA, Hayden MJ, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiology investigation. J Infect Dis 1996;174: 529-36.
21. Colodner R, Rock W, Chazan B, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163-7.
22. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
23. Jacoby GA, Chow N, Waites KB Prevalence of plasmid-mediated quinolone resistance. Antimicrob Agents Chemother 2003;47:559-62.
24. Karas JA, Pillay DG, Muckart D, Sturm AW. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother 1996;37:203-4.
25. imp) in gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol 1996;34:2909-13